Shellye Horowitz shares her story of working through the ups and downs of hemophilia, from carrying factor to school every day to creating safety plans and finding supportive colleagues. She reflects on dreaming big, adapting with confidence, and the belief that hemophilia doesn’t…
Geneventiv Therapeutics said it had a “positive and constructive” meeting with the U.S. Food and Drug Administration (FDA) on its plan to develop GENV-HEM, a gene therapy for hemophilia A. The meeting “represents a key regulatory milestone for Geneventiv,” Damon Race, CEO of Geneventiv, said in a…
Hemophilia B is a rare genetic bleeding disorder that impairs the blood’s ability to clot properly.
Biomarin Pharmaceutical is looking to sell off rights to Roctavian (valoctocogene roxaparvovec-rvox), its approved gene therapy for hemophilia A. “As we focus on the business units aligned with our strategic priorities, today we are announcing the decision to pursue options to divest Roctavian and remove it from…
I have a friend from middle school who has a special place in my heart. We call each other “friends of a lifetime.” Years can pass without us speaking to each other, but we pick up as if no time has passed at all. I am part of her family…
Several years ago, when I was checking some incisions about a week after I had a surgical procedure, I discovered gobs of red, gelatinous goo. No scabs had formed over the incisions like they were supposed to. I have hemophilia, so thankfully, I made it through the surgery safely,…
Hemophilia A is a rare genetic disorder that affects the blood’s ability to clot properly. It is the most common form of hemophilia, responsible for 80% of all cases.
Mim8 (denecimig) is an antibody therapy being developed to prevent or reduce the frequency of bleeding episodes in people with hemophilia A, with or without neutralizing antibodies (inhibitors).
Get regular updates to your inbox.
